Study to Evaluate Initiation of Stalevo in Early Wearing-Off (SENSE)

This study has been completed.
Sponsor:
Information provided by:
Orion Corporation, Orion Pharma
ClinicalTrials.gov Identifier:
NCT00462007
First received: April 17, 2007
Last updated: February 5, 2008
Last verified: February 2008
  Purpose

An open, non-randomised, multinational, multicentre direct switch study in levodopa-treated Parkinson's disease patients suffering from early wearing-off in Parkinson's disease. The study will consist of 2 consecutive periods: screening period and study treatment period. Duration of the study will be up to 8 weeks for each subject. The study treatment dosage will be determined by the subject's current, separately administered standard levodopa/DDCI treatment (3-4 doses per day, maximum of total daily dose of 600 mg levodopa) which will be switched to an equivalent dose of Stalevo® without changing the number of doses per day. The levodopa daily dose during Stalevo® treatment may be adjusted according to the study subject's clinical response.


Condition Intervention Phase
Parkinson's Disease
Drug: Stalevo
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Stalevo® in Subjects With Early Wearing-Off Identified Using a Screening Tool WOQ-9; an Open, Non-Randomised, Multinational, Multicentre 6-Week Direct Switch Study in Levodopa-Treated Parkinson's Disease Patients

Resource links provided by NLM:


Further study details as provided by Orion Corporation, Orion Pharma:

Primary Outcome Measures:
  • Clinical Global Impression of Change (Patient) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical Global Impression of Change (Investigator); United Parkinson's Disease Rating Scale (II, III); Quality of Life Visual Analogue Scale; Wearing-off Questionnaire with 9 symptoms [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Enrollment: 115
Study Start Date: September 2006
Study Completion Date: December 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Stalevo
Drug: Stalevo
Oral 3-4 daily doses for 6 weeks

Detailed Description:

See 'Brief summary'.

  Eligibility

Ages Eligible for Study:   35 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with idiopathic Parkinson's disease and early wearing-off symptoms treated with standard levodopa/DDCI treatment
  • Age >35 - years
  • Hoehn and Yahr stage 1-3 performed during the 'ON'-stage
  • At least 1 symptom identified by WOQ-9
  • Dosing frequency of 3-4 doses of standard-release levodopa/DDCI (maximum total daily dose of 600 mg of levodopa)

Exclusion Criteria:

  • Atypical or symptomatic Parkinson's disease
  • Unpredictable OFF-periods
  • Any peak-dose dyskinesia. 'OFF'-state dystonia is allowed
  • Use of any rescue medications to treat symptoms of 'OFF'-state. 1 dose of soluble levodopa/DDCI is allowed.
  • Concomitant treatment with non-selective monoamine oxidase (MAO) inhibitor or simultaneous use of higher than recommended doses of MAO-A and MAO-B inhibitors (selegiline 10 mg or rasagiline 1 mg allowed) or use of apomorphine.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00462007

Locations
Germany
Humboldt Universität Charité Neurologische Klinik
Berlin, Germany, 10098
St. Josef-Hospital, Klinikum der Ruhr-Universität-Bochum Neurologische Klinik
Bochum, Germany, 44791
Pharmakologisches Studienzentrum Chemnitz
Chemnitz, Germany, 09111
Universitätsklinikum Carl Gustav Carus Klinik und Poliklinik für Neurologie
Dresden, Germany, 01307
Gemeinschaftspraxis für Neurologie & Psychiatrie
Erbach, Germany, 64711
Neurologische Praxis Dr Christine Schuster
Giessen, Germany, 35390
Universitätskrankenhaus Eppendorf
Hamburg, Germany, 20251
Paracelsus-Elena Klinik
Kassel, Germany, 34128
Alexianer-Krankenhaus
Krefeld, Germany, 47805
Nervenarztpraxis Dr Alexander Nass
Köln, Germany, 51069
Universitätsklinikum Gießen und Marburg GmbH
Marburg, Germany, D-35039
Asklepios Fachklinikum Stadtroda
Stadtroda, Germany, 07646
Eberhard-Karls-Universität, Universitätsklinikum Tübingen, Zentrum für Neurologie
Tübingen, Germany, 72076
Neurologische Klinik der Universität Ulm
Ulm, Germany, 89081
Sweden
Länsjukhuset Ryhov, Geriatriska Kliniken
Jönköping, Sweden, 55185
Nyköpings Lasarett, Ger/Rehabkliniken
Nyköping, Sweden, 61185
Visby lasarett, Neurologmottagningen
Visby, Sweden, 62184
United Kingdom
The Royal Bournemouth Hospital, Department of Medicines for the Elderly
Bournemouth, Dorset, United Kingdom, BH7 7DW
North Tyneside General Hospital, Department of Medicine
North Shields, Tyne and Wear, United Kingdom, NE29 8NH
Royal Sussex County Hospital, Neurology Department
Brighton, United Kingdom, BN2 5BE
Sponsors and Collaborators
Orion Corporation, Orion Pharma
Investigators
Principal Investigator: Wolfgang H. Oertel, Professor Universitätsklinikum Giessen und Marburg GmbH
  More Information

No publications provided

Responsible Party: Liisa Luotonen, Orion Pharma
ClinicalTrials.gov Identifier: NCT00462007     History of Changes
Other Study ID Numbers: 2939117
Study First Received: April 17, 2007
Last Updated: February 5, 2008
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
Germany: Federal Institute for Drugs and Medical Devices
Denmark: Danish Medicines Agency
Sweden: Medical Products Agency

Additional relevant MeSH terms:
Parkinson Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders

ClinicalTrials.gov processed this record on October 23, 2014